Brain Metabolic Changes in Developing Brain Due to Chronic Liver Disease: An In Vivo Longitudinal and Multiparametric Study Using 31P MRS, 31P Magnetization Transfer and 1H MRS

2017 ◽  
Vol 7 ◽  
pp. S67-S68
Author(s):  
Veronika Rackayova ◽  
Vladimir Mlynarik ◽  
Cristina Cudalbu
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Magnetization Transfer ◽  
Metabolic Changes ◽  
Chronic Liver ◽  
Developing Brain ◽  
1H Mrs ◽  
31P Mrs

P: 36 Antibiotic Rifaximin for Treatment of Chronic Liver Disease-Induced HE: A Longitudinal In Vivo 1H-MRS Study of Brain Metabolism on BDL Rats

2019 ◽  
Vol 114 (1) ◽  
pp. S18-S19
Author(s):  
Emmanuelle Flatt ◽  
Olivier Braissant ◽  
Stefanita Mitrea ◽  
Dario Sessa ◽  
Rolf Gruetter ◽  
...  
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Brain Metabolism ◽  
Chronic Liver ◽  
1H Mrs

Rifaximin in Chronic Liver Disease-induced Hepatic Encephalopathy: An In Vivo Longitudinal Study of Brain Metabolism on BDL Rats

2017 ◽  
Vol 7 ◽  
pp. S55-S56
Author(s):  
Emmanuelle Flatt ◽  
Cristina Cudalbu ◽  
Olivier Braissant ◽  
Stefan Mitrea ◽  
Dario Sessa ◽  
...  
Keyword(s):  
Liver Disease ◽  
Longitudinal Study ◽  
Hepatic Encephalopathy ◽  
Chronic Liver Disease ◽  
Brain Metabolism ◽  
Chronic Liver

Evaluation of Metabolic Changes in HCV Diabetic Patients Treated With Direct Acting Antiviral Agents

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Engy Yousry Elsayed ◽  
Hany Haroun Saad ◽  
Gina Gamal Naguib ◽  
Hazem Ibrahim Abouelela
Keyword(s):  
Uric Acid ◽  
Hepatitis C Virus ◽  
Liver Disease ◽  
Hepatitis C ◽  
Chronic Liver Disease ◽  
Serum Uric Acid ◽  
Metabolic Changes ◽  
Chronic Liver ◽  
Hcv Infection ◽  
Diabetic Patients

Abstract Background Viral hepatitis is a major public health problem in need of urgent response. The prevalence of hepatitis C virus (HCV) infection in Egypt is the highest in the world. Seroprevalence was modeled to 10.6% and viraemic prevalence to 7.3% in 2014. The association between hepatitis C virus (HCV) infection and diabetes has been widely postulated. Prospective studies have demonstrated a higher risk of developing type 2 diabetes mellitus (T2DM) and insulin resistance in the HCV population. Objective to evaluate metabolic changes in HCV-positive diabetic patients following combination therapy of hepatitis C, clarifying the role of DAAs in these changes. Patients and Methods This study was conducted in Ain Shams University Hospital outpatient clinics who attended from March to December 2018. our study included 70 patients, and were subdivided into the following two groups: Group I: Easy to treat group. Contains 35 diabetic patients with HCV related chronic liver disease treated with sofosbuvir, daclatasvir. Group II: Difficult to treat group. Contains 35 diabetic patients with HCV related chronic liver disease treated with sofosbuvir and daclatasvir and ribavirin. Results Treatment was considered successful when patients became non-viraemic as identified by negative HCV RNA serum PCR at 12 weeks from the end of the treatment regimens (SVR). It was found that diabetic patients treated with DAAs achieved reduction of HbA1C by mean of (0.724±0.3%). The mean increase of serum uric acid level was (0.607±0.4 mg/dL). There were increases in Cholesterol (by mean of 16.85±3.4), HDL (by mean of 5.34±2.1) and LDL (by mean of 13.91±4.2) as well as a decrease in TG (by mean of 13.56±5.1). Conclusion Our study concludes that HCV eradication in diabetic patients leads to various metabolic changes in the form of: Reduction of serum HbA1c level. Elevation of serum uric acid. Elevation of serum cholesterol, HDL, LDL as well as a decrease in TG. Further and larger studies are needed to evaluate the full magnitude of RBV effects on the patients’ metabolism.

scholarly journals IN VIVO AND IN VITRO EXPRESSIONS OF CCR1 AND CCR5 IN PATIENTS WITH ACTIVE SCHISTOSOMIASIS AND CHRONIC LIVER DISEASE

2010 ◽  
Vol 6 (1) ◽  
pp. 45-68
Author(s):  
Samir A. El-Masry ◽  
Mona S. Gouida ◽  
Khalid M. El-azab ◽  
Mahmoud E Nasr
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Chronic Liver

In vivo, high-field, 3-Tesla 1H MR spectroscopic assessment of liver fibrosis in HCV-correlated chronic liver disease

2008 ◽  
Vol 113 (2) ◽  
pp. 289-299 ◽  
Author(s):  
A. Orlacchio ◽  
F. Bolacchi ◽  
M. Angelico ◽  
A. Mancini ◽  
V. Cozzolino ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Chronic Liver Disease ◽  
High Field ◽  
Chronic Liver ◽  
3 Tesla

P: 62 Neurometabolism in Grey Matter of Children With Chronic Liver Disease or Portosystemic Shunting: A 1H-MRS Study at 7T

2019 ◽  
Vol 114 (1) ◽  
pp. S31-S32
Author(s):  
Cristina Cudalbu ◽  
Lijing Xin ◽  
Sarah Lachat ◽  
Nathalie Valenza ◽  
Florence Zangas-Gehri ◽  
...  
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Grey Matter ◽  
Chronic Liver ◽  
1H Mrs ◽  
Portosystemic Shunting

High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo

2005 ◽  
Vol 42 (5) ◽  
pp. 666-673 ◽  
Author(s):  
Frank Tacke ◽  
Torsten Wüstefeld ◽  
Rüdiger Horn ◽  
Tom Luedde ◽  
Annavarapu Srinivas Rao ◽  
...  
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Chronic Liver

scholarly journals Initiation of hepatic stellate cell activation extends into chronic liver disease

2021 ◽  
Vol 12 (12) ◽  
Author(s):  
Vincent De Smet ◽  
Nathalie Eysackers ◽  
Vincent Merens ◽  
Mina Kazemzadeh Dastjerd ◽  
Georg Halder ◽  
...  
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Cell Activation ◽  
Stellate Cell ◽  
Chronic Liver ◽  
Cell Level ◽  
Two Phases ◽  
Druggable Targets

AbstractActivated hepatic stellate cells (aHSC) are the main source of extra cellular matrix in liver fibrosis. Activation is classically divided in two phases: initiation and perpetuation. Currently, HSC-based therapeutic candidates largely focus on targeting the aHSCs in the perpetuation phase. However, the importance of HSC initiation during chronic liver disease (CLD) remains unclear. Here, we identified transcriptional programs of initiating and activated HSCs by RNA sequencing, using in vitro and in vivo mouse models of fibrosis. Importantly, we show that both programs are active in HSCs during murine and human CLD. In human cirrhotic livers, scar associated mesenchymal cells employ both transcriptional programs at the single cell level. Our results indicate that the transcriptional programs that drive the initiation of HSCs are still active in humans suffering from CLD. We conclude that molecules involved in the initiation of HSC activation, or in the maintenance of aHSCs can be considered equally important in the search for druggable targets of chronic liver disease.

Sign in / Sign up

Export Citation Format

Share Document